BFSG LLC’s Ligand Pharmaceuticals LGND Stock Holding History

BFSG LLC’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,898	Closed	-$496K	–	115
2018 Q3	$496K	Buy	+2,898	New	+$437K	0.21%	95

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

BFSG LLC's LGND Position: Q4 2018 in Review

BFSG LLC sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 2,898 shares — an estimated $496K sold.

BFSG LLC first reported a position in LGND in Q3 2018 and held it in 1 quarter. The position peaked at $496K in Q3 2018. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

BFSG LLC reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
BFSG LLC sold 2,898 Ligand Pharmaceuticals shares in Q4 2018, an estimated $496K.
BFSG LLC first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 1 quarter.
BFSG LLC's Ligand Pharmaceuticals position peaked at $496K in Q3 2018.
362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on BFSG LLC's 13F filing for Q4 2018, filed 24 Jan 2019.